ESMO GI 2019: endoscopy vs. surgery for early oesophageal cancer


  • Dawn O'Shea
  • Univadis Medical News
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Endoscopic treatment provides long-term remission or cure in a considerable number of patients with high-risk oesophageal adenocarcinoma (OAC) and may represent a valid alternative to surgery, according to the findings of a new study presented at the 2019 ESMO World Congress on Gastrointestinal Cancer.

In the study, patients with high-risk early oesophageal cancer (EOC) underwent endoscopic resection (ER) or submucosal dissection (ESD). Patients with high-risk EOC without contraindications were referred for surgery (n=24) and 47 continued endoscopic treatment.

In the endoscopy group, complete local remission (CLR) was achieved in 45/47 patients (95.7%). Two patients without CLR continued endoscopic therapy with palliative intent. Tumour generalisation occurred in two patients. Tumour-free survival was 84 months.

One patient in the oesophagectomy group had generalisation revealed during surgery. Local residual malignancy was present in six of the remaining 23 patients.

A total of 484 lymph nodes (LNs) were evaluated. LN metastases were detected in one patient and micrometastases were detected in another two patients. Surgery-related mortality was 4.4 per cent.

The study authors highlight the “surprisingly low” risk of LN metastases and micrometastases and say endoscopic treatment may represent a valid alternative to surgery in this patient population.